Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.
暂无分享，去创建一个
F. Rieux-Laucat | A. Fischer | C. Bodemer | Y. Crow | P. Reix | D. Duffy | M. Rodero | G. Rice | B. Bader-Meunier | A. Belot | M. Frémond | B. Neven | S. Blanche | D. Moshous | T. Walzer | A. Hulin | B. Charbit | D. Bessis | M. Le Bourgeois | M. Fabre | N. Khoudour | E. Jeziorski | N. Jeremiah | L. Berteloot | G. Cros | Consuelo Modesto Caballero